Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-15 02:05Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which could negatively impact its regulatory and commercial prospects [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. - It is important to note that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].